MCID: MLG088
MIFTS: 30

Malignant Germ Cell Tumor

Categories: Rare diseases, Cancer diseases

Aliases & Classifications for Malignant Germ Cell Tumor

MalaCards integrated aliases for Malignant Germ Cell Tumor:

Name: Malignant Germ Cell Tumor 53
Malignant Germ Cell Neoplasm 73
Germ Cell Cancer 73

Classifications:



External Ids:

Summaries for Malignant Germ Cell Tumor

MalaCards based summary : Malignant Germ Cell Tumor, also known as malignant germ cell neoplasm, is related to malignant germ cell tumor of the cervix uteri and malignant germ cell tumor of the vagina. An important gene associated with Malignant Germ Cell Tumor is LDHA (Lactate Dehydrogenase A). The drugs Lenograstim and Etoposide have been mentioned in the context of this disorder. Affiliated tissues include brain, ovary and testis, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and Decreased shRNA abundance (Z-score < -2)

Related Diseases for Malignant Germ Cell Tumor

Graphical network of the top 20 diseases related to Malignant Germ Cell Tumor:



Diseases related to Malignant Germ Cell Tumor

Symptoms & Phenotypes for Malignant Germ Cell Tumor

GenomeRNAi Phenotypes related to Malignant Germ Cell Tumor according to GeneCards Suite gene sharing:

26 (show all 13)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-134 9.8 CGB5
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-145 9.8 LDHA
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-15 9.8 LDHA
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-160 9.8 CGB5
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-179 9.8 LDHA CGB5
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-180 9.8 LDHA
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-184 9.8 LDHA
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-203 9.8 LDHA
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-212 9.8 LDHA
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-38 9.8 LDHA
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-59 9.8 LDHA CGB5
12 Decreased shRNA abundance (Z-score < -2) GR00366-A-68 9.8 LDHA
13 Decreased shRNA abundance (Z-score < -2) GR00366-A-95 9.8 CGB5

Drugs & Therapeutics for Malignant Germ Cell Tumor

Drugs for Malignant Germ Cell Tumor (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 128)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lenograstim Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 135968-09-1
2
Etoposide Approved Phase 3,Phase 2,Phase 1,Not Applicable 33419-42-0 36462
3
Cisplatin Approved Phase 3,Phase 2,Not Applicable 15663-27-1 84093 441203 2767
4
Carboplatin Approved Phase 3,Phase 2,Phase 1,Not Applicable 41575-94-4 10339178 498142 38904
5
Vinblastine Approved Phase 3,Phase 2 865-21-4 13342 241903
6
Ifosfamide Approved Phase 3,Phase 2,Phase 1 3778-73-2 3690
7
Bleomycin Approved, Investigational Phase 3,Phase 2,Not Applicable 11056-06-7 5360373
8
Mechlorethamine Approved, Investigational Phase 3,Phase 2,Phase 1 51-75-2 4033
9
Mesna Approved, Investigational Phase 3,Not Applicable 3375-50-6 598
10
Paclitaxel Approved, Vet_approved Phase 3,Phase 2 33069-62-4 36314
11
Testosterone undecanoate Approved, Investigational Phase 2, Phase 3 5949-44-0
12
Testosterone Approved, Investigational Phase 2, Phase 3 58-22-0 6013
13
Methyltestosterone Approved Phase 2, Phase 3 58-18-4 6010
14
Testosterone enanthate Approved Phase 2, Phase 3 315-37-7 9416
15
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
16
Diphenhydramine Approved, Investigational Phase 3 147-24-0, 58-73-1 3100
17
Promethazine Approved, Investigational Phase 3 60-87-7 4927
18
Cyproheptadine Approved Phase 3 129-03-3 2913
19
Histamine Approved, Investigational Phase 3 75614-87-8, 51-45-6 774
20
Castor oil Approved, Investigational, Nutraceutical, Vet_approved Phase 2, Phase 3 8001-79-4
21
Isophosphamide mustard Phase 3,Phase 2,Phase 1 0
22 Alkylating Agents Phase 3,Phase 2,Phase 1,Not Applicable
23 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1,Not Applicable
24 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1,Not Applicable
25 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1,Not Applicable
26 Etoposide phosphate Phase 3,Phase 2,Phase 1,Not Applicable
27 Antimitotic Agents Phase 3,Phase 2,Phase 1
28 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1,Not Applicable
29 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1,Not Applicable
30 Cathartics Phase 2, Phase 3
31 Adjuvants, Immunologic Phase 3,Phase 2,Phase 1,Not Applicable
32 Albumin-Bound Paclitaxel Phase 3,Phase 2
33 Gastrointestinal Agents Phase 2, Phase 3,Phase 3
34 Anabolic Agents Phase 2, Phase 3
35 Testosterone 17 beta-cypionate Phase 2, Phase 3
36 Androgens Phase 2, Phase 3
37 Hormone Antagonists Phase 2, Phase 3
38 Dermatologic Agents Phase 3,Phase 2
39 Hormones Phase 2, Phase 3
40 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2, Phase 3
41 Laxatives Phase 2, Phase 3
42 Antineoplastic Agents, Hormonal Phase 2, Phase 3
43 Podophyllotoxin Phase 3 518-28-5
44 Dexamethasone acetate Phase 3 1177-87-3
45 Histamine H2 Antagonists Phase 3
46 Keratolytic Agents Phase 3
47 BB 1101 Phase 3
48
Histamine Phosphate Phase 3 51-74-1 65513
49 Serotonin Agents Phase 3
50 Serotonin Antagonists Phase 3

Interventional clinical trials:

(show all 46)
# Name Status NCT ID Phase Drugs
1 Observation and/or Combination Chemotherapy After Surgery or Biopsy in Treating Young Patients With Extracranial Germ Cell Tumors Unknown status NCT00274950 Phase 3 carboplatin;cisplatin;etoposide;ifosfamide;vinblastine sulfate
2 Androgen for Leydig Cell Proliferation Completed NCT01206270 Phase 2, Phase 3 Testosterone undecanoate;Castor Oil
3 Active Surveillance, Bleomycin, Carboplatin, Etoposide, or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors Recruiting NCT03067181 Phase 3 Bleomycin;Carboplatin;Cisplatin;Etoposide
4 Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients With Relapsed or Refractory Germ Cell Tumors Recruiting NCT02375204 Phase 3 paclitaxel;ifosfamide;cisplatin;pegylated G-CSF;G-CSF;carboplatin;etoposide phosphate
5 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
6 Combination Chemotherapy in Treating Young Patients With Recurrent or Resistant Malignant Germ Cell Tumors Completed NCT00467051 Phase 2 paclitaxel;carboplatin;ifosfamide
7 Combination Chemotherapy Plus Amifostine in Treating Children With Malignant Germ Cell Tumors Completed NCT00003811 Phase 2 amifostine trihydrate;cisplatin;etoposide
8 Combination Chemotherapy in Treating Children With Non-testicular Malignant Germ Cell Tumors Completed NCT00002489 Phase 2 carboplatin;cyclophosphamide;doxorubicin hydrochloride;etoposide;leucovorin calcium;methotrexate;vincristine sulfate
9 Phenylbutyrate to Treat Children With Progressive or Recurrent Brain Tumors Completed NCT00006450 Phase 2 Phenylbutyrate
10 Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia Completed NCT01154816 Phase 2 Alisertib
11 Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment Completed NCT00091182 Phase 2 oxaliplatin
12 Neoadjuvant Chemotherapy With or Without Second-Look Surgery Followed by Radiation Therapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Intracranial Germ Cell Tumors Completed NCT00047320 Phase 2 carboplatin;etoposide;ifosfamide;thiotepa
13 High-Dose Thiotepa Plus Peripheral Stem Cell Transplantation in Treating Patients With Refractory Solid Tumors Completed NCT00003173 Phase 2 thiotepa
14 Arsenic Trioxide in Treating Patients With Advanced Neuroblastoma or Other Childhood Solid Tumors Completed NCT00024258 Phase 2 arsenic trioxide
15 A Multicenter Study to Evaluate a Risk-adapted Strategy for Treatment of Extra Cranial Non Seminomateous Malignant Germ Cell Tumour in Children and Adolescent Recruiting NCT02104986 Phase 2 Velbe-Bleomycin-Cisplatin;Vepeside-ifosfamide-Cisplatin
16 Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial) Recruiting NCT03526250 Phase 2 Palbociclib
17 PI3K/mTOR Inhibitor LY3023414 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial) Recruiting NCT03213678 Phase 2 PI3K/mTOR Inhibitor LY3023414
18 Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial) Recruiting NCT03213704 Phase 2 Larotrectinib
19 Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) Recruiting NCT03155620 Phase 2 Ensartinib;Erdafitinib;Larotrectinib;Olaparib;Palbociclib;PI3K/mTOR Inhibitor LY3023414;Selumetinib Sulfate;Tazemetostat;Vemurafenib
20 Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial) Recruiting NCT03220035 Phase 2 Vemurafenib
21 Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial) Recruiting NCT03233204 Phase 2 Olaparib
22 Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial) Recruiting NCT03210714 Phase 2 Erdafitinib
23 Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors Active, not recruiting NCT00788125 Phase 1, Phase 2 carboplatin;dasatinib;etoposide phosphate;ifosfamide
24 Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial) Suspended NCT03213665 Phase 2 Tazemetostat
25 Melphalan, Carboplatin, Mannitol, and Sodium Thiosulfate in Treating Patients With Recurrent or Progressive CNS Embryonal or Germ Cell Tumors Suspended NCT00983398 Phase 1, Phase 2 Carboplatin;Mannitol;Melphalan;Sodium Thiosulfate
26 Peripheral Stem Cell Transplantation Plus Chemotherapy in Treating Patients With Malignant Solid Tumors Unknown status NCT00007813 Phase 1 carboplatin;cyclophosphamide;etoposide
27 Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma Completed NCT00994500 Phase 1 vorinostat;bortezomib
28 Liposomal Doxorubicin in Treating Children With Refractory Solid Tumors Completed NCT00019630 Phase 1 doxorubicin HCl liposome
29 Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas Completed NCT00101270 Phase 1 irinotecan hydrochloride;oxaliplatin
30 Erlotinib and Temozolomide in Treating Young Patients With Recurrent or Refractory Solid Tumors Completed NCT00077454 Phase 1 erlotinib hydrochloride;temozolomide
31 Flavopiridol in Treating Children With Relapsed or Refractory Solid Tumors or Lymphomas Completed NCT00012181 Phase 1 alvocidib
32 PTC299 in Treating Young Patients With Refractory or Recurrent Primary Central Nervous System Tumors Completed NCT01158300 Phase 1 VEGF inhibitor PTC299
33 Talabostat Combined With Temozolomide or Carboplatin in Treating Young Patients With Relapsed or Refractory Brain Tumors or Other Solid Tumors Completed NCT00303940 Phase 1 carboplatin;talabostat mesylate;temozolomide
34 ABT-751 in Treating Young Patients With Refractory Solid Tumors Completed NCT00036959 Phase 1 ABT-751
35 Ixabepilone in Treating Young Patients With Solid Tumors or Leukemia That Haven't Responded to Therapy Completed NCT00030108 Phase 1 ixabepilone
36 Temozolomide and O6-benzylguanine in Treating Children With Solid Tumors Completed NCT00020150 Phase 1 O6-benzylguanine;temozolomide
37 Busulfan in Treating Children and Adolescents With Refractory CNS Cancer Completed NCT00006246 Phase 1 busulfan
38 Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagnosed or Relapsed Solid Tumor Active, not recruiting NCT00638898 Phase 1 busulfan;melphalan;topotecan hydrochloride
39 Amifostine to Protect From Side Effects of PSCT in Treating Patients With Solid Tumors Terminated NCT00003926 Phase 1 amifostine trihydrate;busulfan;filgrastim;melphalan;thiotepa
40 Etoposide, Carboplatin, and Bleomycin in Treating Young Patients Undergoing Surgery For Malignant Germ Cell Tumors Unknown status NCT00276718 Not Applicable carboplatin;etoposide
41 Cancer and Hearing Loss Related in Children Unknown status NCT02425397
42 Studying Biomarkers in Samples From Younger Patients With Malignant Germ Cell Tumor Progression Completed NCT01433224
43 Combination Chemotherapy in Treating Children With Newly Diagnosed Malignant Germ Cell Tumors Completed NCT00066482 Not Applicable cisplatin;cyclophosphamide;etoposide
44 Development of Strategies to Increase Enrollment in Clinical Trials for Children With Cancer Completed NCT00002485
45 Collecting and Storing Tissue From Young Patients With Cancer Recruiting NCT00898755
46 Differences in Trends Malignant Germ Cell Tumors in Males and Females: A SEER Population-based Study Withdrawn NCT00322790

Search NIH Clinical Center for Malignant Germ Cell Tumor

Genetic Tests for Malignant Germ Cell Tumor

Anatomical Context for Malignant Germ Cell Tumor

MalaCards organs/tissues related to Malignant Germ Cell Tumor:

41
Brain, Ovary, Testis, Testes, Liver, Lymph Node, Pineal

Publications for Malignant Germ Cell Tumor

Articles related to Malignant Germ Cell Tumor:

(show top 50) (show all 83)
# Title Authors Year
1
Erratum: Pashankar F, Hale JP, Dang H, et al. Is adjuvant chemotherapy indicated in ovarian immature teratomas? A combined data analysis from the Malignant Germ Cell Tumor International Collaborative. Cancer. 2016;122:230-237. ( 29509324 )
2018
2
Novel loss of function mutation in KRIT1/CCM1 is associated with distinctly progressive cerebral and spinal cavernous malformations after radiochemotherapy for intracranial malignant germ cell tumor. ( 28488085 )
2017
3
Safety and efficacy of bleomycin/pingyangmycin-containing chemotherapy regimens for malignant germ cell tumor patients in the female genital system. ( 28160575 )
2017
4
Is adjuvant chemotherapy indicated in ovarian immature teratomas? A combined data analysis from the Malignant Germ Cell Tumor International Collaborative. ( 26485622 )
2016
5
Swyer's Syndrome with Mixed Ovarian Malignant Germ Cell Tumor and Ovarian Gonadoblastoma. ( 27411466 )
2016
6
Abdominal wall mixed malignant germ cell tumor: a case report and review of literature. ( 29787026 )
2016
7
Treatment Results of Extracranial Malignant Germ Cell Tumor with Regimens of Cisplatin, Vinblastine, Bleomycin or Carboplatin, Etoposide, and Bleomycin with Special Emphasis on the Sites of Vagina and Testis. ( 25769700 )
2015
8
Metastatic Treated Malignant Germ Cell Tumors: Is SALL4 a Better Marker Than Placental Alkaline Phosphatase? ( 25906119 )
2015
9
Neo-adjuvant chemotherapy in the treatment of advanced malignant germ cell tumors of ovary. ( 24145115 )
2014
10
Feto-maternal outcomes of pregnancy complicated by ovarian malignant germ cell tumor: a systematic review of literature. ( 25150953 )
2014
11
Impact of central surgical review in a study of malignant germ cell tumors. ( 25783295 )
2014
12
Two case reports of a malignant germ cell tumor of ovary and a granulosa cell tumor: interest of tumoral immunochemistry in the identification and management. ( 24982844 )
2014
13
Sacrococcygeal malignant germ cell tumor (SC-MGCT) with intraspinal extension. ( 24952799 )
2014
14
Utility of OCT3/4, TSPY and I^-catenin as biological markers for gonadoblastoma formation and malignant germ cell tumor development in dysgenetic gonads. ( 23396295 )
2013
15
Brain metastases during follow-up of children and adolescents with extracranial malignant germ cell tumors: risk adapted management decision tree analysis based on data of the MAHO/MAKEI-registry. ( 22693072 )
2013
16
Outcomes of combined modality therapy for patients with stage III or IV mediastinal malignant germ cell tumors. ( 23553421 )
2013
17
High-dose chemotherapy followed by autologous peripheral blood stem cell transplantation for recurrent primary mediastinal malignant germ cell tumor: A case report. ( 24373121 )
2013
18
Is there a role for carboplatin in the treatment of malignant germ cell tumors? A systematic review of adult and pediatric trials. ( 22976789 )
2013
19
Usefulness of OCT4/3 immunostain in pediatric malignant germ cell tumors. ( 22506928 )
2013
20
LIN28 Expression in malignant germ cell tumors downregulates let-7 and increases oncogene levels. ( 23774216 )
2013
21
Delayed Recognition of Disorders of Sex Development (DSD): A Missed Opportunity for Early Diagnosis of Malignant Germ Cell Tumors. ( 22315593 )
2012
22
A rare case of solitary metastatic non-seminomatous malignant germ cell tumor to the prostate. ( 23040630 )
2012
23
Diagnostic utility of CD117, CD133, SALL4, OCT4, TCL1 and glypican-3 in malignant germ cell tumors of the ovary. ( 22448662 )
2012
24
[Prognostic factors analysis in patients with ovarian malignant germ cell tumor treated with fertility-preserving surgery]. ( 23324188 )
2012
25
Overexpression of karyopherin 2 in human ovarian malignant germ cell tumor correlates with poor prognosis. ( 22962582 )
2012
26
CDX-2 expression in malignant germ cell tumors of the testes, intratubular germ cell neoplasia, and normal seminiferous tubules. ( 22895825 )
2012
27
Extracranial malignant germ cell tumors. ( 22706911 )
2012
28
Identification of microRNAs From the miR-371~373 and miR-302 clusters as potential serum biomarkers of malignant germ cell tumors. ( 21173133 )
2011
29
Evaluation of neoadjuvant therapy in patients with nongerminomatous malignant germ cell tumors. ( 21456918 )
2011
30
Unusual liver locations of growing teratoma syndrome in ovarian malignant germ cell tumors. ( 24371596 )
2011
31
Malignant germ cell tumors associated with Swyer syndrome. ( 21225934 )
2011
32
Therapy-associated secondary tumors in patients with non-germinomatous malignant germ cell tumors. ( 21533838 )
2011
33
Modified grading system for clinical outcome of intracranial non-germinomatous malignant germ cell tumors. ( 22966355 )
2010
34
Rete testis invasion by malignant germ cell tumor and/or intratubular germ cell neoplasia: what is the significance of this finding? ( 20573373 )
2010
35
Malignant germ cell tumors display common microRNA profiles resulting in global changes in expression of messenger RNA targets. ( 20332240 )
2010
36
Family history of cancer and malignant germ cell tumors in children: a report from the Children's Oncology Group. ( 19842050 )
2010
37
Proton beam therapy for loco-regional control of a recurrent mixed malignant germ cell tumor of the skull in a 22-month-old girl. ( 20514623 )
2010
38
Survival after an antiangiogenetic therapy and surgery in a wide spread growing teratoma originating from a testicular mixed malignant germ cell tumor. ( 19437360 )
2009
39
Carbon 11-labeled methionine positron emission tomography for detection of residual viable tumor cells after adjuvant therapy in nongerminomatous malignant germ cell tumors in 2 cases including an autopsy case. ( 18262610 )
2009
40
Clinicopathologic characteristics of malignant germ cell tumors in the ovaries of Korean women: a Korean Gynecologic Oncology Group Study. ( 19258947 )
2009
41
Pediatric malignant germ cell tumors show characteristic transcriptome profiles. ( 18519683 )
2008
42
The prevalence and prognostic impact of lymph node metastasis in malignant germ cell tumors of the ovary. ( 18571705 )
2008
43
False-positive serum human chorionic gonadotropin (HCG) in a male patient with a malignant germ cell tumor of the testis: a case report and review of the literature. ( 18984875 )
2008
44
Comprehensive staging allows for excellent outcome in patients with localized malignant germ cell tumor of the ovary. ( 18948812 )
2008
45
Malignant germ cell tumors of the ovary: a review of 41 cases and risk factors for recurrence. ( 19115694 )
2008
46
Diagnostic value of lectin reactive alpha-fetoprotein for neoinfantile hepatic tumors and malignant germ cell tumors: preliminary study. ( 18525461 )
2008
47
Regression pattern of alpha fetoprotein level changed after treatment of malignant germ cell tumor. ( 18575279 )
2008
48
Chemotherapy for the treatment of children and adolescents with malignant germ cell tumors. ( 18612144 )
2008
49
Viable malignant germ cell tumor in the postchemotherapy retroperitoneal lymph node dissection specimen: can it be predicted using clinical parameters? ( 16944534 )
2006
50
High lactate dehydrogenase isoenzyme 1 in a patient with malignant germ cell tumor is attributable to aberrant methylation of the LDHA gene. ( 15297388 )
2004

Variations for Malignant Germ Cell Tumor

Expression for Malignant Germ Cell Tumor

Search GEO for disease gene expression data for Malignant Germ Cell Tumor.

Pathways for Malignant Germ Cell Tumor

GO Terms for Malignant Germ Cell Tumor

Sources for Malignant Germ Cell Tumor

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....